MedTrace Logo

Cardiotoxicity of Targeted Therapy for HER-2 Positive Breast Cancer Patients at High Altitude

NCT05063643 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 132

Last updated 2021-10-01

No results posted yet for this study

Summary

This is a prospective, multicenter, cohort study aiming to explore the cardiotoxicity of targeted therapy for HER-2 positive breast cancer patients who lives in high altitude area. One hundred and thirty two HER-2 positive breast cancer patients who will receive neoadjuvant, adjuvant, or palliative targeted therapy will be enrolled. The cardiotoxicity of targeted therapy will be observed and recorded during the treatment and one year after the end of treatment. The subjects will be stratified by age, baseline cardiac risk factors, and anthracyclines.

Conditions

Interventions

OTHER

High altitude

High altitude is defined as \>2000m.

Sponsors & Collaborators

  • Affiliated Hospital of Qinghai University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-31
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05063643 on ClinicalTrials.gov